IBC Review Processes

The UNC Charlotte Institutional Biosafety Committee (IBC) is to review all recombinant DNA research conducted at or sponsored by UNC Charlotte faculty, students, staff to verify all protocols meet or exceed the standards outlined in the NIH Guidelines, and approves those research projects that comply with the Guidelines in accordance with the publication of the Biosafety and Microbiological and Biomedical Laboratories (6th ed). The IBC is also charged with the review and oversight of research involving microorganisms pathogenic to humans, plants, or animals; biological select agents and toxins (BSAT); and biological material from human or non-human primates and animals.

Initial Review

All biosafety applications receive an initial review by the Biosafety Office, in consultation with the Biosafety Officer (BSO) and Institutional Biosafety Committee Chair, to determine appropriate risk group (RG) and biosafety containment levels (BSL). If additional information is required, the Biosafety Office will contact the investigator.

Applications proposing the use of recombinant/synthetic nucleic acid molecules will be reviewed against the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to determine whether the proposed use is considered exempt from—or subject to—NIH Guidelines.

Turnaround Time

Please allow 3-6 weeks for review and approval of biohazard research proposed at BSL-2/RG-2 or BSL-3/RG-3. Review and assessment of BSL-1/RG-1 and exempt recombinant or synthetic nucleic acid molecule work may occur in less time.

All IBC Review Scenarios

  • BSL-1 & Exempt recombinant or synthetic nucleic acid molecule work: click here.
  • BSL-2 or BSL-3 submissions eligible for Designated IBC Member (DMR) review: click here.
  • Submissions requiring Full Committee Review (FCR) at a convened meeting: click here.

Institutional Review Entity (IRE)

A sub-committee of the IBC, along with expert advisors, established to review research proposals involving biological agents and toxins that may pose risks to public health, agriculture, food security, economic security, or national security. This review is conducted in accordance with the USG Policy for Oversight of Dual Use Research of Concern (DURC) and Pathogens with Enhanced Pandemic Potential (PEPP) effective May5, 2025.

Need more information? Contact:

Biosafety Program 704-687-1825